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aTATE-OF-THE-ART PAPER2067Novel Anticoagulants for Stroke Prevention in AFtephan H. Schirmer, Magnus Baumhäkel, Hans-Ruprecht Neuberger, Stefan H. Hohnloser,
sabelle C. van Gelder, Gregory Y. H. Lip, Michael Böhm
ntithrombotic therapy using aspirin or vitamin K antagonists for prevention of ischemic
troke in patients with atrial fibrillation (AF) is limited by its narrow therapeutic range and
he need for regular monitoring of its dosing. This review by Schirmer and colleagues reviews
ecent advances in the development of directly acting oral anticoagulant drugs, including the
irect thrombin antagonist dabigatran and the factor Xa inhibitors rivaroxaban, apixaban,
etrixaban and edoxaban. Currently, phase III clinical trial efficacy for stroke prevention is
vailable only for dabigatran, but several other agents have shown efficacy for preventing
enous thromboembolism and are being studied for AF stroke prevention.VIEWPOINT AND COMMENTARY IEWPOINT AND COMMENTARYHeart Failure Guidelines, Performance Measures, and the Practice of Medicine2077alal K. Ghali, Barry M. Massie, Douglas L. Mann, Michael W. Rich
2081rederick A. Masoudi, Eric D. Peterson, Jeffrey L. Anderson, Robert O. Bonow, Alice K. Jacobs
lthough they are meant to supplement rather than replace clinical judgment, Ghali and
olleagues argue that guidelines for clinical care have been widely perceived and accepted as
efining appropriate and inappropriate medical care. There are important limitations to the
vidence base used to formulate these guidelines: many are derived from expert consensus,
nd there are significant differences in patients enrolled in randomized controlled trials and
hose seen in community practice. Using performance measures synthesized from these
uidelines and reimbursement strategies that rely on these performance measures may
iminish the importance of physician judgment and lead to inappropriate interventions. An
ccompanying commentary by several members of the Task Force on Practice Guidelines and
ask Force on Performance Measures addresses these concerns, emphasizing that the
reamble to every guideline states that the recommendations are to be used as general guides
nd that patient care decisions are ultimately to be made by the treating clinician in view of
ll of the circumstances presented by a specific patient.
(continued on page A-30)
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ENTERVENTIONAL CARDIOLOGY2084EES Improve Outcomes in Nondiabetic Patients Compared With PESean J. Kereiakes, Donald E. Cutlip, Robert J. Applegate, John Wang, Manejeh Yaqub, Poornima Sood,
iaolu Su, Guoping Su, Naim Farhat, Ali Rizvi, Charles A. Simonton, Krishnankutty Sudhir,
regg W. Stone
ereiakes and colleagues compared the safety and efficacy of an everolimus-eluting stent
EES) with a paclitaxel-eluting stent (PES) stratified by diabetic status in the SPIRIT IV
Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) trial.
he primary end point was the occurrence of target lesion failure (TLF) at 1 year. EES
ompared with PES reduced the 1-year rate of TLF by 54% in nondiabetic patients (3.1% vs.
.7%), but there was no difference in the rates of TLF in diabetic patients. Further studies are
eeded to determine the cause of this differential effectiveness.EART FAILURE
2090uiding HF Treatments With Individualized
NT-proBNP Levels Does Not Improve Outcomesuc W. M. Eurlings, Petra E. J. van Pol, Wouter E. Kok, Sandra van Wijk, Cara Lodewijks-van der Bolt,
ggie H. M. M. Balk, Dirk J. A. Lok, Harry J. G. M. Crijns, Dave J. W. van Kraaij, Nicolaas de Jonge,
oan G. Meeder, Martin Prins, Yigal M. Pinto
he PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure
Mprove heart fAilure morbidity and mortality?) study sought to determine if titrating heart
ailure (HF) therapies to individualized target N-terminal pro-brain natriuretic peptide
NT-proBNP) levels would improve outcomes. Subjects hospitalized for decompensated
F were randomized after discharge to either clinically-guided outpatient management
r management guided by an individually-set NT-proBNP target. The target was defined
s 10% over the lowest level at discharge or 2 weeks thereafter. Clinicians were alerted
hen the level was increased above this level. There was no difference during 2 years of
ollow-up in the primary end point, which was days alive outside of the hospital after
ndex admission.
ditorial Comment: Richard W. Troughton, Chris M. Frampton, M. Gary Nicholls, p. 2101(continued on page A-34)
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bERIPHERAL ARTERY DISEASE2105Smoking Cessation Program Effective for Patients With PADeborah Hennrikus, Anne M. Joseph, Harry A. Lando, Sue Duval, Laurie Ukestad, Molly Kodl,
lan T. Hirsch
ennrikus and colleagues tested the effectiveness of a smoking cessation program designed for
atients with peripheral arterial disease (PAD). Outpatients with PAD who were cigarette
mokers were randomly assigned to an intensive tailored PAD-specific counseling
ntervention or a minimal intervention. Participants randomized to the intensive intervention
roup were significantly more likely to be confirmed abstinent at 6-month follow-up (21% vs.
%). These results show that many long-term smokers with PAD are willing to initiate a
erious attempt to quit and that an intensive smoking cessation program can increase the
uccessful quit rate.ditorial Comment: Elizabeth A. Jackson, Kim A. Eagle, p. 2113PRE-CLINICAL RESEARCH RE-CLINICAL RESEARCH2115Cannabidiol May Attenuate Diabetic Cardiomyopathyohanraj Rajesh, Partha Mukhopadhyay, Sa´ndor Ba´tkai, Vivek Patel, Keita Saito, Shingo Matsumoto,
oshihiro Kashiwaya, Béla Horva´th, Bani Mukhopadhyay, Lauren Becker, György Hasko´, Lucas Liaudet,
avid A. Wink, Aristidis Veves, Raphael Mechoulam, Pa´l Pacher
annabidiol (CBD), the most abundant nonpsychoactive constituent of the marijuana plant,
xerts anti-inflammatory effects. Rajesh and colleagues investigated the effects of CBD on
iabetic cardiomyopathy in a mouse model and with human cardiomyocytes exposed to high
lucose. CBD attenuated myocardial dysfunction, cardiac fibrosis, oxidative/nitrosative stress,
nflammation, cell death, and inter-related signaling pathways in the mouse model. CBD also
ttenuated the high glucose-induced increased reactive oxygen species generation, nuclear
actor-B activation, and cell death in primary human cardiomyocytes. These results suggest
hat CBD may be useful for treating diabetic complications.YEAR IN CARDIOLOGY SERIES EAR IN CARDIOLOGY SERIES2126The Year in Non-ST-Segment Elevation Acute Coronary Syndromeobert P. Giugliano, Eugene Braunwald
iugliano and Braunwald highlight publications between June 2009 and May 2010 in the
eld of non–ST-segment elevation acute coronary syndromes (NSTE-ACS). Among the
ighlights is a review and commentary on the several new trials, as well as secondary analyses
rom prior studies, regarding each of the 4 currently recommended parenteral anticoagulants
n NSTE-ACS (unfractionated heparin, enoxaparin, bivalirudin, and fondaparinux). Data on
he newer thienopyridines are discussed, as are the controversies regarding the interactions
etween clopidogrel and proton-pump inhibitors and the CYP2C19 genotype.
